GeneDx Holdings Corp.

NasdaqGS WGS

GeneDx Holdings Corp. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -21.48%

GeneDx Holdings Corp. EBITDA Margin is -21.48% for the Trailing 12 Months (TTM) ending September 30, 2024, a 88.66% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

GeneDx Holdings Corp. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -189.33%, a -42.10% change year over year.
GeneDx Holdings Corp. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -133.24%, a 5.82% change year over year.
GeneDx Holdings Corp. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -141.46%.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NasdaqGS: WGS

GeneDx Holdings Corp.

CEO	Ms. Katherine A. Stueland
IPO Date	Nov. 4, 2020
Location	United States
Headquarters	North Tower
Employees	1,000
Sector	Healthcare
Industries Telehealth Artificial Intelligence (AI) Autonomous Driving Big Data Biotechnology Clinical Trials Pharmaceuticals Robotics

Description

GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.

Key trends

Past 5 years